Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study

Mark S. Freedman, Nicola De Stefano, Frederik Barkhof, Chris H. Polman, Giancarlo Comi, Bernard M J Uitdehaag, Florence Casset-Semanaz, Brian Hennessy, Lorenz Lehr, Bettina Stubinski, Dominic L. Jack, Ludwig Kappos

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The REFLEX study (NCT00404352) established that subcutaneous (sc) interferon (IFN) β-1a reduced the risks of McDonald MS (2005 criteria) and clinically definite multiple sclerosis (CDMS) in patients with a first clinical demyelinating event suggestive of MS. The aim of this subgroup analysis was to assess the treatment effect of sc IFN β-1a in patient subgroups defined by baseline disease and demographic characteristics (age, sex, use of steroids at the first event, classification of first event as mono- or multifocal, presence/absence of gadolinium-enhancing lesions, count of

Original languageEnglish
Pages (from-to)490-499
Number of pages10
JournalJournal of Neurology
Volume261
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Interferons
Multiple Sclerosis
Gadolinium
Sex Characteristics
Steroids
Demography
Therapeutics

Keywords

  • Clinically definite MS
  • Clinically isolated syndrome
  • First clinical demyelinating event
  • Interferon beta
  • McDonald MS

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. / Freedman, Mark S.; De Stefano, Nicola; Barkhof, Frederik; Polman, Chris H.; Comi, Giancarlo; Uitdehaag, Bernard M J; Casset-Semanaz, Florence; Hennessy, Brian; Lehr, Lorenz; Stubinski, Bettina; Jack, Dominic L.; Kappos, Ludwig.

In: Journal of Neurology, Vol. 261, No. 3, 2014, p. 490-499.

Research output: Contribution to journalArticle

Freedman, MS, De Stefano, N, Barkhof, F, Polman, CH, Comi, G, Uitdehaag, BMJ, Casset-Semanaz, F, Hennessy, B, Lehr, L, Stubinski, B, Jack, DL & Kappos, L 2014, 'Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study', Journal of Neurology, vol. 261, no. 3, pp. 490-499. https://doi.org/10.1007/s00415-013-7222-6
Freedman, Mark S. ; De Stefano, Nicola ; Barkhof, Frederik ; Polman, Chris H. ; Comi, Giancarlo ; Uitdehaag, Bernard M J ; Casset-Semanaz, Florence ; Hennessy, Brian ; Lehr, Lorenz ; Stubinski, Bettina ; Jack, Dominic L. ; Kappos, Ludwig. / Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. In: Journal of Neurology. 2014 ; Vol. 261, No. 3. pp. 490-499.
@article{e7cd56602f1f438488f9368977a9b814,
title = "Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study",
abstract = "The REFLEX study (NCT00404352) established that subcutaneous (sc) interferon (IFN) β-1a reduced the risks of McDonald MS (2005 criteria) and clinically definite multiple sclerosis (CDMS) in patients with a first clinical demyelinating event suggestive of MS. The aim of this subgroup analysis was to assess the treatment effect of sc IFN β-1a in patient subgroups defined by baseline disease and demographic characteristics (age, sex, use of steroids at the first event, classification of first event as mono- or multifocal, presence/absence of gadolinium-enhancing lesions, count of",
keywords = "Clinically definite MS, Clinically isolated syndrome, First clinical demyelinating event, Interferon beta, McDonald MS",
author = "Freedman, {Mark S.} and {De Stefano}, Nicola and Frederik Barkhof and Polman, {Chris H.} and Giancarlo Comi and Uitdehaag, {Bernard M J} and Florence Casset-Semanaz and Brian Hennessy and Lorenz Lehr and Bettina Stubinski and Jack, {Dominic L.} and Ludwig Kappos",
year = "2014",
doi = "10.1007/s00415-013-7222-6",
language = "English",
volume = "261",
pages = "490--499",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "3",

}

TY - JOUR

T1 - Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study

AU - Freedman, Mark S.

AU - De Stefano, Nicola

AU - Barkhof, Frederik

AU - Polman, Chris H.

AU - Comi, Giancarlo

AU - Uitdehaag, Bernard M J

AU - Casset-Semanaz, Florence

AU - Hennessy, Brian

AU - Lehr, Lorenz

AU - Stubinski, Bettina

AU - Jack, Dominic L.

AU - Kappos, Ludwig

PY - 2014

Y1 - 2014

N2 - The REFLEX study (NCT00404352) established that subcutaneous (sc) interferon (IFN) β-1a reduced the risks of McDonald MS (2005 criteria) and clinically definite multiple sclerosis (CDMS) in patients with a first clinical demyelinating event suggestive of MS. The aim of this subgroup analysis was to assess the treatment effect of sc IFN β-1a in patient subgroups defined by baseline disease and demographic characteristics (age, sex, use of steroids at the first event, classification of first event as mono- or multifocal, presence/absence of gadolinium-enhancing lesions, count of

AB - The REFLEX study (NCT00404352) established that subcutaneous (sc) interferon (IFN) β-1a reduced the risks of McDonald MS (2005 criteria) and clinically definite multiple sclerosis (CDMS) in patients with a first clinical demyelinating event suggestive of MS. The aim of this subgroup analysis was to assess the treatment effect of sc IFN β-1a in patient subgroups defined by baseline disease and demographic characteristics (age, sex, use of steroids at the first event, classification of first event as mono- or multifocal, presence/absence of gadolinium-enhancing lesions, count of

KW - Clinically definite MS

KW - Clinically isolated syndrome

KW - First clinical demyelinating event

KW - Interferon beta

KW - McDonald MS

UR - http://www.scopus.com/inward/record.url?scp=84896491309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896491309&partnerID=8YFLogxK

U2 - 10.1007/s00415-013-7222-6

DO - 10.1007/s00415-013-7222-6

M3 - Article

VL - 261

SP - 490

EP - 499

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 3

ER -